Survodutide Protocol
GLP-1/glucagon dual receptor agonist studied for weight management and liver-fat research.
- Standard dose
- 3.3 mg
- Frequency
- 1× weekly, subcutaneous
- Route
- subcutaneous
- Cycle
- 12–24 weeks
- Vial
- 5 mg
Evidence Level: Emerging Evidence
Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.
Human evidence: Phase 2 trials with published weight and liver-fat outcomes; Phase 3 programs ongoing.
Animal evidence: Preclinical dual-agonist metabolic studies.
Introduction & Mechanism of Action
GLP-1/glucagon dual receptor agonist studied for weight management and liver-fat research.
Balanced dual agonism combines GLP-1-driven appetite suppression with glucagon-receptor-driven hepatic lipid oxidation, a mechanism of particular research interest for liver-fat (NASH) endpoints.
Receptors/targets: GLP-1 receptor, Glucagon receptor
Areas of Research Interest
- GLP-1/glucagon dual-agonist research
- Liver-fat (NASH) studies
- Weight-management research
Benefits Reported in Research
- Weight-management research
- Liver-fat marker studies
- Metabolic research
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 0.6–6 mg
Reported frequency: 1× weekly, subcutaneous
Reported cycle duration: 12–24 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on Survodutide reports administration at 0.6–6 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | subcutaneous | 1× weekly, subcutaneous | 3.3 mg |
Reconstitution Reference
Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for Survodutide →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 5 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 2.50 mg/mL.
- 03
Reported Research Administration
Published research describes 1× weekly, subcutaneous administration via subcutaneous route, at 3.3 mg per administration.
- 04
Cycle Reference
Published protocols describe a cycle duration of 12–24 weeks. Consult a physician before beginning any new research cycle.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Pregnancy
Drug interactions
- Insulin/sulfonylureas — increased hypoglycemia risk
- Delayed gastric emptying may affect concurrent oral drug absorption
Safety
- Gastrointestinal intolerance
- Theoretical glucagon-related glycemic effects
- Gallbladder-related events
Not yet a generally authorized medicine; hepatic and metabolic endpoints are still being established across trial populations.
Expected Results & Comparison
Survodutide and Mazdutide share the same GLP-1/glucagon dual-agonist mechanism; Survodutide's trial program has a stronger published emphasis on liver-fat (NASH) endpoints specifically.